Immuno-Oncology

Latest News

July 25th 2016

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

July 25th 2016

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

By Anas Younes, MD

July 25th 2016

Novel Combination Study Planned for SCLC

By Silas Inman

July 20th 2016

Where Immuno-Oncology Is Heading

July 20th 2016

Brentuximab Vedotin in Advanced Lymphoid Malignancies

Latest Videos

Future Research Efforts for ALK-Driven Lung Cancer

Next Generation ALK Inhibitors for NSCLC

$Treatment of ALK-Driven Refractory NSCLC$

Treatment of ALK-Driven Refractory NSCLC

Sequencing Therapies in ALK+ NSCLC

Upfront Use of Second-Line Agents in ALK+ NSCLC

$Treatment of Relapsed/Refractory ALK+ NSCLC$

Treatment of Relapsed/Refractory ALK+ NSCLC

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

FDA Approval of Brigatinib for ALK+ NSCLC

Patterns of Progression on Crizotinib for ALK+ NSCLC

CME Content

Virtual Event

Tennessee Oncology Practice Society

1 Session is Available!

Immuno-Oncology

Latest News

Latest Videos

Future Research Efforts for ALK-Driven Lung Cancer

Next Generation ALK Inhibitors for NSCLC

Treatment of ALK-Driven Refractory NSCLC

Sequencing Therapies in ALK+ NSCLC

Upfront Use of Second-Line Agents in ALK+ NSCLC

Treatment of Relapsed/Refractory ALK+ NSCLC

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

FDA Approval of Brigatinib for ALK+ NSCLC

Patterns of Progression on Crizotinib for ALK+ NSCLC

CME Content

Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Minnesota

Live Tumor Board: Decoding Neuroendocrine Neoplasms – Practical Advances in Diagnostics, Emerging Treatments, and Real-World Management

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Louisiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Missouri Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Iowa Oncology Society

Washington State Medical Oncology Society

Indiana Oncology Society

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Missouri Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

New Mexico Society of Clinical Oncology

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Nevada Oncology Society

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Montana State Oncology Society

Wisconsin Association of Hematology and Oncology

Rhode Island Oncology Society

21st Annual New York Lung Cancers Symposium®

South Carolina Oncology Society

Texas Society of Clinical Oncology

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

Kentucky Society of Clinical Oncology

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

(CPE Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

More News

Anti-CD20 Antibodies for Advanced Hematologic Malignancies